PresentationsFirst Demonstration of Targeted Protein Degradation of BTK in Hematologic Malignancies: Initial NX-2127 Phase 1a PK/PD Data By AldenMC Production / October 27, 2021
PresentationsNX-5948, a Selective Degrader of BTK, Significantly Reduces Inflammation in a Model of Autoimmune Disease By AldenMC Production / June 2, 2021
PresentationsSmall molecule inhibition of the ubiquitin ligase CBL-B with NX-1607 results in potent T and NK cell mediated anti-tumor response By AldenMC Production / April 10, 2021
PresentationsNX-2127, a Degrader of BTK and IMiD Neosubstrates, for the Treatment of B-Cell Malignancies By AldenMC Production / December 7, 2020
PresentationsTargeted Protein Modulation: Harnessing or Inhibiting E3 Ligases to Decrease or Increase Protein Levels By AldenMC Production / October 14, 2020
